IPP Bureau

Nona Biosciences expands platform to accelerate early clinical trials
Nona Biosciences expands platform to accelerate early clinical trials

By IPP Bureau - December 27, 2025

Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards

AB Science secures US patent for Masitinib in sickle cell disease till 2040
AB Science secures US patent for Masitinib in sickle cell disease till 2040

By IPP Bureau - December 27, 2025

Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain

FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia
FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia

By IPP Bureau - December 27, 2025

The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia

Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA

By IPP Bureau - December 26, 2025

These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products

Teva moves within reach of investment grade as S&P upgrades credit rating & Moody’s positive
Teva moves within reach of investment grade as S&P upgrades credit rating & Moody’s positive

By IPP Bureau - December 26, 2025

Dr Kaustav Talapatra named ASTRO’s International Ambassador from India
Dr Kaustav Talapatra named ASTRO’s International Ambassador from India

By IPP Bureau - December 26, 2025

Sanofi to acquire Dynavax in $2.2 billion deal, bolstering adult vaccine portfolio
Sanofi to acquire Dynavax in $2.2 billion deal, bolstering adult vaccine portfolio

By IPP Bureau - December 26, 2025

The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities

Japan nod to Dupixent for children with severe asthma
Japan nod to Dupixent for children with severe asthma

By IPP Bureau - December 26, 2025

The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies

Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access
Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access

By IPP Bureau - December 26, 2025

BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia

Cipla launches needle-free inhalable insulin Afrezza in India
Cipla launches needle-free inhalable insulin Afrezza in India

By IPP Bureau - December 26, 2025

Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge

Kashiv BioSciences secures Rs. 684 crore funding to build one of India’s largest biopharma facilities
Kashiv BioSciences secures Rs. 684 crore funding to build one of India’s largest biopharma facilities

By IPP Bureau - December 26, 2025

The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals

Apollo Pharmacy hits 1,000 stores in Karnataka
Apollo Pharmacy hits 1,000 stores in Karnataka

By IPP Bureau - December 26, 2025

The opening of our 1000th pharmacy in Karnataka marks an important step

Lunit SCOPE matches pathologist accuracy in HER2 scoring for advanced biliary tract cancer
Lunit SCOPE matches pathologist accuracy in HER2 scoring for advanced biliary tract cancer

By IPP Bureau - December 25, 2025

Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology

Tanabe Pharma America transfers RADICAVA business to Shionogi
Tanabe Pharma America transfers RADICAVA business to Shionogi

By IPP Bureau - December 25, 2025

U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS

Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor

By IPP Bureau - December 25, 2025

Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China

Latest Stories

Interviews

Packaging